- Home
- BEATW vs SLGN Comparison
BEATW vs SLGN Comparison
Compare BEATW & SLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- SLGN
- Stock Information
- Founded
- BEATW 2015
- SLGN 1987
- Country
- BEATW United States
- SLGN United States
- Employees
- BEATW 20
- SLGN N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- SLGN Containers/Packaging
- Sector
- BEATW Technology
- SLGN Industrials
- Exchange
- BEATW Nasdaq
- SLGN Nasdaq
- Market Cap
- BEATW N/A
- SLGN N/A
- IPO Year
- BEATW N/A
- SLGN 1997
- Fundamental
- Price
- BEATW $0.51
- SLGN $51.61
- Analyst Decision
- BEATW
- SLGN Strong Buy
- Analyst Count
- BEATW 0
- SLGN 9
- Target Price
- BEATW N/A
- SLGN $64.22
- AVG Volume (30 Days)
- BEATW 4.7K
- SLGN 889.9K
- Earning Date
- BEATW 03-14-2025
- SLGN 04-30-2025
- Dividend Yield
- BEATW N/A
- SLGN 1.56%
- EPS Growth
- BEATW N/A
- SLGN N/A
- EPS
- BEATW N/A
- SLGN 2.58
- Revenue
- BEATW N/A
- SLGN $5,854,694,000.00
- Revenue This Year
- BEATW N/A
- SLGN $11.91
- Revenue Next Year
- BEATW N/A
- SLGN $2.58
- P/E Ratio
- BEATW N/A
- SLGN $19.88
- Revenue Growth
- BEATW N/A
- SLGN N/A
- 52 Week Low
- BEATW $0.50
- SLGN $41.14
- 52 Week High
- BEATW $0.62
- SLGN $58.14
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- SLGN 51.98
- Support Level
- BEATW N/A
- SLGN $50.22
- Resistance Level
- BEATW N/A
- SLGN $51.85
- Average True Range (ATR)
- BEATW 0.00
- SLGN 0.94
- MACD
- BEATW 0.00
- SLGN 0.27
- Stochastic Oscillator
- BEATW 0.00
- SLGN 92.23
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.